AZD8701,一种针对FOXP3mRNA的反意义寡核酸,作为单疗法和与杜尔瓦卢马布联合使用:在患有高级固体瘤的患者中进行I期试验
Lillian L Siu1, Sophie Postel-Vinay2, Rafael Villanueva-Vázquez3
1Princess Margaret Cancer Centre, Toronto, Canada.
概括
这一第一阶段研究表明,针对FOXP3的抗意义寡核酸AZD8701在先进的固体瘤中具有临床可行性. 该疗法证明了可管理的安全性和成功地传递给瘤,支持进一步研究这种新型免疫疗法方法.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 表达FOXP3的调节性T细胞 (Tregs) 抑制抗瘤免疫力.
- 反感性寡核酸 (ASO) 技术提供有针对性的基因沉默.
- 开发新的免疫疗法来克服瘤诱导的免疫抑制是至关重要的.
研究的目的:
- 评估AZD8701的安全性和耐受性,这是一个针对FOXP3的下一代ASO,用于晚期固体瘤患者.
- 为了确定AZD8701单独或与杜尔瓦卢马布联合使用时的最大耐受剂量 (MTD).
- 评估AZD8701.1的初步疗效和生物活性.
主要方法:
- 一期临床试验,招募先前通过标准护理治疗的高级固体瘤患者.
- 剂量升级AZD8701每周一次静脉注射,单独或与杜尔瓦卢马布一起使用.
- 主要终点包括安全性,耐受性和MTD;次要终点包括客观反应率和FOXP3表达水平.
主要成果:
- 一般来说,AZD8701的耐受性很好,并有可控的不良事件. 疲劳和阿氨酸转移酶的增加是常见的.
- 在AZD8701 (960毫克) 的最高剂量下观察到增加的阿兰氨基转移酶的一个剂量限制性毒性.
- 观察到瘤反应,包括很大一部分患者的稳定疾病和组合手臂的一次部分反应. 观察到异质的FOXP3 mRNA减少,在瘤组织中检测到ASO.
结论:
- 针对FOXP3的反感性寡核酸AZD8701在患有高级固体瘤的患者中具有临床可行性.
- AZD8701的安全性概况是可以管理的,支持其进一步的临床开发.
- 有证据表明,瘤的目标参与 (FOXP3敲击) 和ASO传递给瘤,验证了治疗方法.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.2K
07:04Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
224
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
